NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date (Ascending) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
51285-0368-01 | 51285-0368 | Methotrexate | Trexall | 10.0 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 3, 2001 | In Use | |
51285-0369-01 | 51285-0369 | Methotrexate | Trexall | 15.0 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | May 3, 2001 | In Use | |
51672-4118-02 | 51672-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | March 17, 2017 | In Use | |
51672-4118-05 | 51672-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | March 17, 2017 | In Use | |
51672-4118-06 | 51672-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | March 17, 2017 | In Use | |
50242-0130-01 | 50242-0130 | ALECTINIB HYDROCHLORIDE | Alecensa | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Dec. 11, 2015 | In Use | |
50242-0130-86 | 50242-0130 | ALECTINIB HYDROCHLORIDE | Alecensa | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Oct. 10, 2017 | In Use | |
54569-1818-09 | 54569-1818 | METHOTREXATE, Methotrexate sodium | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 7, 1953 | In Use | |
54868-5474-00 | 54868-5474 | Erlotinib Hydrochloride | Tarceva | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 21, 2005 | In Use | |
55111-0556-10 | 55111-0556 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 11, 2013 | In Use | |
57962-0070-28 | 57962-0070 | Ibrutinib | IMBRUVICA | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Dec. 20, 2017 | In Use | |
57962-0140-09 | 57962-0140 | Ibrutinib | Imbruvica | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Nov. 13, 2013 | In Use | |
57962-0140-12 | 57962-0140 | Ibrutinib | Imbruvica | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Nov. 13, 2013 | In Use | |
57962-0280-28 | 57962-0280 | Ibrutinib | IMBRUVICA | 280.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb. 16, 2018 | In Use | |
57962-0420-28 | 57962-0420 | Ibrutinib | IMBRUVICA | 420.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb. 16, 2018 | In Use | |
57962-0420-71 | 57962-0420 | Ibrutinib | IMBRUVICA | 420.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb. 6, 2019 | In Use | |
60687-0149-94 | 60687-0149 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 7, 2016 | In Use | |
61703-0309-06 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Jan. 1, 1996 | In Use | |
61703-0309-16 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Jan. 1, 1996 | In Use | |
61703-0309-25 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Nov. 27, 2013 | In Use | |
61703-0309-26 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Feb. 19, 2014 | In Use | |
61703-0323-22 | 61703-0323 | Bleomycin | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | April 10, 2000 | In Use | |
61703-0332-18 | 61703-0332 | Bleomycin | Bleomycin | 15.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | April 11, 2000 | In Use | |
61703-0339-18 | 61703-0339 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 14, 2004 | In Use | |
61703-0339-22 | 61703-0339 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 14, 2004 | In Use |
Found 10,000 results in 7 milliseconds — Export these results